Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.

Notably, treatment with anakinra as a single agent and anakinra+erlotinib (but not erlotinib alone) either significantly suppressed or showed a trend toward the suppression of IL-1α (Figure 7A ), IL-1β (Figure 7B ) and G-CSF (Figure 7C ) in ER-SQ20B tumors compared to control treated tumors.

also in 53,322 other papers